Over £100mn in fines for pharma firms hiking prices of crucial thyroid drug
The Competition and Markets Authority fines Advanz and two others for hiking prices of liothyronine tablets by 1,110 percent in eight years.
List view / Grid view
The Competition and Markets Authority fines Advanz and two others for hiking prices of liothyronine tablets by 1,110 percent in eight years.
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.